Pulmonx (LUNG)

• Market cap: $83.7M
• 1 day: 2.09%
• 5 days: 2.63%
• 1 month: -12.56%
• 3 months: 56%
• 6 months: 21.12%
• Year to date: -15.22%
• 1 year: 23.42%
• 5 years: -95.01%
• 10 years: -95.04%
• Sector: Healthcare
• Industry: Medical Devices

About: Pulmonx Corp is a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). solution, which is comprised of the Zephyr Endobronchial Valve (Zephyr Valve), the Chartis Pulmonary Assessment System (Chartis System), and the LungTraX Platform, is designed to treat severe emphysema patients who, despite medical management, are still profoundly symptomatic and either do not want or are ineligible for surgical approaches. The majority of the company's revenue is generated from the provision of cloud hosting and management services. The company geographically, operates in the USA, the EMEA, the Asia Pacific, and other international regions, the majority of revenue from USA.

Employees: 296